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DNA double-strand breaks constitute the most dangerous type of DNA damage induced by ionising radiation (IR). Accordingly, the
resistance of cells to IR is modulated by three intimately related cellular processes: DNA repair, recombination, and replication.
Significant discoveries in this field of research have been made over the last few years. A picture seems to be emerging in which
perturbations of recombination in cancer cells are a more widespread cause of genomic instability than previously appreciated.
Conversely, such cells may also be more sensitive to certain chemotherapeutic drugs and to IR. Thus, the alterations in recombination
that promote carcinogenesis by causing genomic instability may also be the weakness of the tumours that arise in this setting, a
concept which could hold great promise for the advancement of cancer treatment in the not too distant future.
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Exposure of the cellular DNA to ionising radiation (IR) inflicts
various types of damage (Steel, 1996). It is established that the
creation of a DNA double-strand break (DSB) represents the
principal lesion that, if not adequately repaired, can lead to cell
death via the generation of lethal chromosomal aberrations or the
direct induction of apoptosis. Alternatively, an inaccurately
repaired or unrepaired DSB may result in mutations or genomic
rearrangements in a surviving cell, which in turn can lead to
genomic instability and subsequently result in malignant cell
transformation. Complex damage response pathways have evolved,
and are evolutionary conserved, to protect the cell from the
potentially deleterious effects of a DSB. Two principal recombina-
tional repair pathways have been recognised, homologous
recombination (HR) and nonhomologous end-joining (NHEJ),
that employ entirely separate protein complexes. Briefly, DSB
repair by HR requires an undamaged template molecule that
contains a homologous DNA sequence, typically on the sister
chromatid in the S and G2 phases of the cell cycle. In contrast,
nonhomologous re-joining of two double-stranded DNA ends,
which may occur in all cell-cycle phases, does not require an
undamaged partner and does not rely on extensive homologies
between the recombining ends. The study of these pathways has
proved to be a rapidly evolving field of research over the past few
years. Considerable interest has been generated by the realisation
that defective HR and, in some cases, NHEJ can be causally linked
to impaired DNA replication, genomic instability, human chro-
mosomal instability syndromes, cancer development, or cellular
hypersensitivity to DNA-damaging agents.
Here, we discuss some of the recent advancements in basic
research on DNA repair, recombination, and replication, which
could hold great promise for the advancement of cancer treatment
in the not too distant future. To this end, the prevailing theme is
that the genetic alterations in recombination that lead to genomic
instability and malignant transformation may also determine how
tumour cells respond to IR and certain chemotherapeutic drugs
(Venkitaraman, 2003). We are only able to consider a small
number of studies for the purposes of this mini-review. For further
details on the molecular mechanisms and genetic determinants of
HR and NHEJ, the reader is referred to recent review articles
(Abraham, 2001; Khanna and Jackson, 2001; Pierce et al, 2001;
Thompson and Schild, 2001; Jackson, 2002; Willers et al, 2002;
Alberts, 2003; Powell and Kachnic, 2003).
FROM REPLICATION TO RADIATION RESISTANCE
While exogenous DSBs are induced by IR or drugs such as
bleomycin or etoposide, endogenous DSBs arise as byproducts of
normal intracellular metabolism. It has been estimated that the
spontaneous rate of endogenous DSBs may be as high as 50 breaks
per cell per cell cycle (Vilenchik and Knudson, 2003). For example,
DSBs can be detected when replication forks stall and collapse, a
process that is thought to occur frequently during the S-phase. The
cell can repair and/or restart replication forks by multiple
mechanisms (Haber and Heyer, 2001), but the major mechanism
that deals with replication-associated DSBs is HR. Intriguingly,
replication intermediates can be deliberately broken or cleaved by
the Mus81 endonuclease complex and the resulting DSB allows
homology-mediated strand invasion, damage bypass, and recon-
stitution of the replication fork. The essential role of HR in
replication is illustrated by the pronounced proliferative defect and
embryonic lethality of mice with knockouts of genes that control
HR, including the Rad51 recombinase or the breast cancer
susceptibility genes BRCA2 or BRCA1 (Powell and Kachnic,
2003). Indeed, it has been suggested that the primary reason for
the existence of HR is the maintenance of functional replication
(Klein and Kreuzer, 2002). It is now clear that the cell takes
advantage of the HR machinery to repair exogenous DSBs as well.
Chromatid breaks in the S and G2 cell-cycle phases may be
predominantly repaired by using the sister chromatid as a
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impaired DNA replication and enhanced IR sensitivity (Thompson
and Schild, 2001; Powell and Kachnic, 2003). Moreover, impaired
HR is also associated with, typically pronounced, hypersensitivity
to DNA inter-strand crosslinks (ICLs), which result from cellular
exposure to cytotoxic agents such as platinum compounds or
mitomycin C.
However, the relationship between the control of replication and
repair of IR-induced DSBs is likely not straightforward because
DNA lesions caused by IR may not always be ideal substrates for
repair by HR mechanisms that are normally employed during
replication restart. IR typically generates clusters of ionisations,
each containing at least 10 ionisations within a diameter of
perhaps five or more nanometers (Steel, 1996). If such an event
impinges on DNA, with the diameter of the double helix being
approximately 2.5nm, it would be expected to cause considerable
local damage, including DSBs, single-strand breaks, and base
damage. The repair of such a clustered damage site may be
complex and/or slow and perhaps under a genetic control that has
only partial overlap with the removal of endogenous DSBs. Indeed,
mutations in genes that are involved in HR and replication often
cause only modest or no radiation hypersensitivity. For example,
the anti-recombinogenic effects of the BLM helicase, mutated in
Bloom’s Syndrome, or the p53 tumour suppressor are not thought
to significantly modulate cellular radiation resistance (Dahm-
Daphi, 2000; Thompson and Schild, 2001; Bo ¨hnke et al, 2004).
Mutations in other genes that act in HR have been reported to
increase radiation sensitivity by only B2-fold or less (Thompson
and Schild, 2001). In general, mutations in NHEJ genes lead to
greater radiation hypersensitivity than mutations in HR genes,
suggesting that NHEJ is the dominant pathway for the removal of
IR-induced DSBs. However, it is possible that this relationship
changes when IR is combined with radiosensitising chemotherapy,
which is the case in many cancer treatments.
Is there also a role for NHEJ in the repair of replication-
associated DSBs? While it is difficult to envision how NHEJ should
contribute to the restart of collapsed replication forks, NHEJ has
been suggested to contribute to the repair of DSBs in the S-phase
(Rothkamm et al, 2003). It is likely that the balance of NHEJ and
HR in the removal of DSBs depends on the type and location of the
lesion, among other factors. Of note, NHEJ is inherently error-
prone and mutagenic, because this process is unable to faithfully
restore the original DNA sequence, as opposed to HR, and because
NHEJ itself can introduce sequence changes during repair. Still,
NHEJ is suggested to be the dominant DSB repair pathway in
mammalian cells, which is in part related to the fact that only a
very small fraction of the genome is coding for genes and
regulatory elements, and that small sequence changes are tolerated
by the cells.
Replication, recombination, and repair are intricately linked and
cannot be studied separately (Klein and Kreuzer, 2002; Alberts,
2003). It follows that it should be of crucial importance to
understand the genetic determinants and molecular mechanisms
of replication in tumour cells, in order to predict the effectiveness
and outcome of cancer therapy. For example, the suggested
primary role of the BRCA1/2-defined pathway is to facilitate HR in
the bypass of stalled replication forks. As to the question of how
cancer arises in cells with deficiencies in BRCA1 or BRCA2, it
seems likely that the impaired function of HR is a key step, since
this is the only established defect in BRCA2-deficient cells (Powell
et al, 2002; Powell and Kachnic, 2003). A mutator phenotype can
be triggered by a defect in the regulation of HR, either by making
the process error-prone or by shunting repair events into a NHEJ
pathway that is inherently mutagenic. Additional yet unknown
mutational steps to bypass the proliferative block are also
necessary so that net growth in the number of cancer cells can
occur. It remains unsolved why this described defect in HR leads to
the tissue-specific cancers of the breast and ovary. Proliferation in
breast or ovarian epithelium may be associated with higher levels
of endogenous DNA damage, relative to other tissues, which leads
to replication stalling and requires HR. It is likely that defective HR
in BRCA1/2-mutant tumour cells also underlies their hypersensi-
tivity to IR and DNA crosslinking agents, which may ultimately
impact on the chances of combination cancer therapy to achieve
tumour eradication. However, to date there is no consistent
evidence that BRCA1/2-mutant tumours carry a higher likelihood
of radiocurability, but this is in large part due to the fact that
residual tumour burden is the critical determinant of local control.
Disentangling the complex relationship between tumour cell
replication, genomic instability, cellular hypersensitivity to DNA-
damaging agents, and clinical tumour control will be an area of
great research interest in the years to come.
DNA DAMAGE RESPONSE: 4D NOT 2D
Cells respond to exogenous and endogenous DSBs through a
cascade of proteins ranging from sensors, which recognise the
damage, through signal and mediator proteins to a series of
downstream effectors that induce cell-cycle arrests, complete
repair by homologous or nonhomologous mechanisms, or
alternatively trigger cell death by apoptosis (for a review,
Abraham, 2001; Jackson, 2002). A simplified illustration is shown
in Figure 1A. Defects at almost any step of this response pathway
can result in measurable alterations of DNA repair by HR and/or
NHEJ. Mutations upstream in the cascade, before the decision is
made whether a lesion is repaired by HR or NHEJ, can directly
affect both principal recombinational repair pathways. For
example, mutation of the upstream kinase ATM, which is mutated
in ataxia telangiectasia (AT), impairs HR and NHEJ (Luo et al,
1996; Khanna and Jackson, 2001), although it is yet unclear
whether these alterations underlie the pronounced radiation
hypersensitivity of AT cells. Loss of the Mre11 protein, which is
mutant in the AT-like disorder (ATLD) and is usually found in a
complex with Nbs1 and Rad50 (MRN complex), reduces both HR
and NHEJ, which likely contributes to radiation hypersensitivity
(Zhang et al, 2004; Zhang et al, unpublished). The MRN complex
may be involved in the processing of DNA ends, among other
functions, prior to the repair by HR or NHEJ. Both of the tumour
suppressors p53 and BRCA1 control aspects of HR and NHEJ
(Willers et al, 2000; Akyuz et al, 2002; Zhang et al, 2004; Willers
et al, unpublished; Dahm-Daphi et al, unpublished), but the
impact of these regulations on radiation resistance is a subject of
active study. FANC-D2, which is mutated in a small subset of
patients with the rare cancer predisposition and chromosomal
instability syndrome Fanconi anaemia (FA), is likely implicated in
HR via its protein interaction with BRCA2 (i.e., FANC-D1)
(Howlett et al, 2002) and confers cellular radiation resistance –
in contrast to most of the other genes in the FA pathway. Similarly,
mutations of genes involved in execution of HR, such as BRCA2 or
Rad51, compromise HR and radiation resistance, while mutations
in the pathway controlled by DNA-PK affect radiation resistance
via disruption of NHEJ. Increasing evidence points towards the
existence of multiple subpathways of HR and NHEJ (Tutt et al,
2001; Akyuz et al, 2002; Jackson, 2002; Zhang et al, 2004), which
will further complicate the understanding of the determinants of
radiation resistance.
The illustration of the DNA damage response in a linear form
(Figure 1A) should not be misleading. Several layers of complexity
need to be considered. Response pathways do not represent linear
sequences of events, but involve complex networks that include
signaling cascades and feedback loops. The control of cell-cycle
progression, DNA repair, and stress responses are not separate
entities, but intricately linked. Thus, it is not surprising that many
regulator and mediator proteins, such as BRCA1 or p53, appear to
have pleiotropic functions in the response to genotoxic stress
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they are components of multiple protein machines, which form at
specific DNA damage sites. These machines represent sets of 10 or
more spatially positioned interacting proteins that undergo highly
ordered movements in a machine-like assembly (Figure 1B)
(Alberts, 2003). When sets of proteins that can function in either
replication, recombination, or repair processes assemble, it is
crucial that their activities are highly regulated and applied only
when and where they are needed. In other words, the multi-protein
complexes that form in response to damaged DNA represent
dynamic entities both in time and in subnuclear location.
Examples include the BRCA1-associated genome surveillance
complex (BASC), which contains in addition to BRCA1 proteins
such as the BLM helicase and the MRN complex, but not BRCA2
(Wang et al, 2000), or the suggested dynamic formation of
recombinosomes including Rad51, Rad52, and Rad54 at sub-
nuclear damage sites (Essers et al, 2002). Therefore, the DNA
damage response should be viewed as a four-dimensional system
rather than as the linear, two-dimensional cascade that is typically
drawn.
The concept of highly ordered and regulated protein machines
at DNA damage sites may have profound implications for the
interpretation of observed alterations in recombination-associated
genes. Amino-acid changes in recombinational proteins have been
increasingly reported in both sporadic tumours and in normal cells
(Pierce et al, 2001; Mohrenweiser et al, 2003). Often, it is unclear
whether such changes represent polymorphisms without func-
tional consequences or (hypomorphic) mutations. Given the
highly ordered nature of the described protein machines, small
structural changes introduced by single amino-acid changes in
individual proteins may already alter the activity of the complex
significantly. Indeed, it appears that there is increasing evidence
that mild reductions in DNA repair capacity, assumed to be the
consequence of common genetic variation in the human popula-
tion, affect cancer predisposition (Mohrenweiser et al, 2003), and,
by inference, possibly modulate the response to radiation
treatment as well.
IMPAIRED RECOMBINATION: THE ACHILLES’ HEEL
OF CANCERS?
As we already discussed, mutations in the BRCA1–BRCA2–Rad51
pathway are associated with defective HR, and these may not only
result in genomic instability but also determine the resistance of
tumour cells to exogenous DSBs or ICLs. Conversely, inappropri-
ate upregulation of HR activities could also contribute to genomic
instability by causing homology-mediated aberrations such as
certain chromosomal translocations or loss of heterozygosity.
Some of these observations may be linked either to the observed
overexpression of the Rad51 protein in several cell types or to the
widespread disruption of pathways controlled by the p53 gene
(Maacke et al, 2000; Linke et al, 2003), but it is yet unclear how
these alterations affect radiation resistance (in the absence of
apoptosis) (Albrechtsen et al, 1999; Dahm-Daphi, 2000; Bo ¨hnke
et al, 2004). A direct clinical application of impaired HR control
was suggested recently by the finding that the activity of the FA
pathway, as determined by the methylation status of the FANC-F
gene, dictated the sensitivity of several ovarian tumours to
cisplatin (Taniguchi et al, 2003). Disruption of the pathway was
found in 8–21% of tumours. An attractive hypothesis to be tested
in clinical studies will be whether also methylation of BRCA1 in a
significant fraction of sporadic breast and ovarian cancers, and
possibly of FANC-F in breast tumours, can determine the response
of such cancers to treatment with cross-linking drugs. Whether it
will be possible to use the functional status of the FA pathway to
predict the clinical tumour response to IR seems to be less clear.
In contrast to HR, there is as yet relatively little suggestion that
implicates perturbed NHEJ pathways in the aetiology of genomic
instability in solid cancers (Pierce et al, 2001; Jackson, 2002). In a
mouse model, heterozygosity of DNA ligase IV, which is involved
in NHEJ, promoted the development of soft-tissue sarcomas that
possessed clonal amplifications, deletions, and translocations
(Sharpless et al, 2001). Clinical correlation is still lacking, but in
one recent report the SYT–SSX fusion gene controlled the
expression of the NHEJ gene XRCC4 in a synovial sarcoma cell
line (Xie et al, 2003). Interestingly, the cytotoxic agent Ecteinasci-
din 743 (ET-743), which has activity against soft tissue sarcomas,
was found to exhibit increased toxicity in cells with defective NHEJ
(Damia et al, 2001). It is tempting to speculate that, analogously to
HR, both reduced or upregulated NHEJ can contribute to genomic
instability at least in some tumour types and determine the cellular
response to drugs that target NHEJ pathways.
Sensor proteins
Rad9-Rad1-Hus1
Upstream kinases
ATR, ATM, Chk2
Mediators/regulators
M/R/N, BRCA1, p53
Effector proteins
Cell-cycle response Apoptotic response
HR NHEJ
B
A
Rad51 and paralogues,
BRCA2, Rad52, Rad54,
XRCC2, XRCC3
Ku70, Ku86,
DNA-PKcs, Artemis,
XRCC4, LigaseIV
4D 4D
Figure 1 Principles of the cellular response to DSBs. (A) Replication
arrest/damage or DSBs, such as induced by IR, are sensed by a set of
proteins that include the ‘9–1–1’ complex (Rad9–Rad1–Hus1). The early
responses kinases ATM, mainly acting on DSBs, and ATR, mainly acting on
replication-associated damage, phosphorylate an extensive and partly
overlapping spectrum of substrates. Upstream kinases and regulator/
mediator proteins, in addition to including the Chk2 kinase, the Mre11/
Rad50/Nbs1 complex (MRN), BRCA1 and p53 among others, affect
recombinational repair, cell-cycle control, and stress and apoptotic
responses. Repair processes by HR and NHEJ are genetically defined by
distinct sets of effector protein complexes. (B) The damage response
involves multiprotein complexes that are dynamic in chromosomal location
and time (i.e., are regarded as four-dimensional entities).
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recombinational repair in cancer cells are a more widespread cause
of genomic instability than previously appreciated. Conversely,
such cells may also be more sensitive to certain chemotherapeutic
drugs and IR. Thus, the alterations in recombination that promote
carcinogenesis by causing genomic instability may also be the
Achilles’ heel of the cancers that arise in this setting (Figure 2)
(Venkitaraman, 2003).
CONCEPTS OF THERAPEUTIC GAIN
Therapeutic gain is defined by a better relation between the killing
of tumour and normal cells in a patient. The central goal of
curative radiation therapy is to optimise therapeutic gain by
maximising the likelihood of killing all clonogenic tumour cells,
while keeping the damage to the surrounding normal tissues to a
minimum. We distinguish between acute (or early) and late
occurring normal tissue damage. Actively proliferating tissues
such as mucosa typically express treatment-induced damage early.
In contrast, in slow or nonproliferating tissues, such as the spinal
cord or the kidneys, it can take many years before radiation
damage becomes clinically manifest. While for the application of
chemotherapy acute toxicity is typically dose-limiting, the total
radiation dose that can be administered is typically limited by the
development of late occurring normal tissue complications. Thus,
in its simplest conception, targeting recombinational repair
pathways could achieve therapeutic gain by the following
mechanism: a novel combination of IR and a drug that disrupts
HR pathways would preferentially kill proliferating tumour cells
that are in S- or G2-phase and thus repair DSBs predominantly by
interchromatid HR. Therapeutic gain will result, especially in
relation to non- or slowly proliferating normal cells, which are
largely in the G0- or G1-phase and repair mainly via NHEJ,
because no sister chromatid is available. However, tumour cells
that are quiescent and nonproliferating (such as hypoxic cells) may
not be hit.
Alternatively, the presence of genetic mutations that shift DSB
repair in cancer cells from NHEJ to the preferential use of HR
pathways, including not only the inter-chromatid repair but also
intra- or inter-chromosomal homology-mediated repair in G1,
may confer particular susceptibility to novel drugs that disrupt
HR. Such mutations could include the p53 gene, inactivation of
which has been reported to result in elevated HR (Willers et al,
2000; Akyuz et al, 2002). In contrast, if mutations are already
present in genes that promote HR, treatment with crosslinking
agents such as cisplatin with or without IR should result in
therapeutic gain.
Therefore, we envision that genotyping and/or phenotyping of
individual cancers for DSB repair pathways could lead to a better
prediction of how a tumour will respond to radiation therapy and
certain chemotherapeutic agents that aim to generate lethal levels
of DSBs in the target cells (Jackson, 2002). In addition, it may be
necessary to analyse DSB repair in the normal tissues prior to
therapy, because inherited alleles that contribute to genomic
instability and carcinogenesis might also result in cellular
radiation hypersensitivity. However, to date, inherited mutant
alleles are usually present only in the heterozygous state, and loss
of heterozygosity to homozygous deficient is only found in tumour
cells.
CONCLUSIONS: THE ‘R’S’ OF RADIATION RESIS-
TANCE
Here, we have focused on some of the concepts and principles in
the study of DNA replication, recombination, and repair (the three
‘R’s’). These processes, which can no longer be considered
separately, form a new paradigm for the understanding of the
cellular resistance to radiation treatment. Genetic mutations in
recombinational processes that affect replication and DSB repair
may not only promote genomic instability but also determine the
response of tumours to combination therapies with DNA
damaging agents. This concept may provide the framework for
future pre-clinical and clinical studies that discover and test novel
combination therapies and tailor these to individual tumours.
While some of our considerations are speculative at the present
time, we anticipate that the rapid progress in this exciting field of
research will continue over the next few years and provide many of
the answers. Finally, although the focus of this review has been the
contribution of cellular radiation resistance to the clinical tumour
response, it is clear that additional factors, such as the contribution
of the tumour microenvironment, are at least equally important in
determining the likelihood of achieving tumour control and cure.
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